Special Issue "Obesity as a Risk Factor for Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 October 2018)
Prof. Dr. Stephan Herzig
The worldwide increase in obesity constitutes a major medical challenge, with high BMI (body mass index) being an important risk factor for disease. In addition to cardiovascular disorders and development of diabetes, obesity increases the risk for developing cancer. There is convincing evidence, which links obesity with the risk for developing cancers of the esophagus, pancreas, colon, breast, liver, kidney and some hematological malignancies and several mechanisms have been proposed to explain this association. Obesity can result in chronic systemic inflammation, which can drive cancer initiation and influence metastasis. Furthermore, a shift in gut microbiota and thus altered microbial metabolite secretion was suggested to influence tumor development. Obesity is associated with changes in hormone levels with insulin being just one example, which can increase cell growth and survival via increasing intracellular pro-tumorigenic signaling. However, adipokines like leptin and adiponectin were also shown to have an impact on tumor behavior. In recent years, the crosstalk of adipose tissue and immune cells with the tumor has become a focus of investigation. These examples illustrate that systemic metabolism can influence different aspects of tumor development through multiple mechanisms, many of which are not well understood. For instance, there is only limited information on the functional interaction between obesity and the metabolic reprogramming of cancer cells favoring tumor development or how obesity influences tumor maintenance and recurrence.
This Special Issue will highlight the role of obesity as a risk factor for cancer, addressing the molecular mechanisms on the role of obesity in tumor initiation, maintenance and recurrence, cancer intrinsic metabolic alterations and tissue crosstalk with the tumor in obese conditions. The collected reviews will, thereby, shine a light on future therapeutic strategies targeting metabolic cancer etiologies.
Prof. Dr. Stephan Herzig
Dr. Götz Hartleben
Dr. Mauricio Berriel Diaz
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer development
- metabolic reprogramming
- tissue-tumor crosstalk